UPDATED: FDA inspects three Merck KGaA plants along EU supply chain

The FDA found problems at three Merck KGaA API and drug manufacturing facilities along a single supply chain in Europe last summer from which ingredients were fed to a plant in Germany. It is unusual for the FDA to inspect different plants along the supply chain simultaneously, Pharmalot notes, and the connected inspections came as the agency was still feeling the heat from the Heparin scandal. FDA warning | Story

Editor's Note: This story had an incorrect stock symbol for Merck KGaA. The story has been updated and corrected.

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.